Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Wai Chun Bio-Technology Ltd. ( (HK:0660) ) has provided an update.
Wai Chun Bio-Technology Limited reported a sharp rise in revenue to HK$352.2 million for the six months ended 31 December 2025, up from HK$161.1 million a year earlier, with gross profit improving to HK$35.7 million. Despite the stronger top line, the group remained loss-making, posting a net loss of HK$5.7 million, though this represented a narrowed deficit compared with the HK$13.1 million loss in the prior-year period.
Higher selling and administrative expenses offset some of the revenue gains, while impairment losses on trade receivables and finance costs continued to weigh on results. Loss attributable to shareholders improved to HK$5.9 million from HK$13.7 million, and basic and diluted loss per share narrowed to 3.33 HK cents from 7.97 HK cents, signaling progress in reducing losses but highlighting that the company has yet to return to profitability.
More about Wai Chun Bio-Technology Ltd.
Wai Chun Bio-Technology Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates through subsidiaries as a bio-technology group. The company generates revenue from its product and service lines in the bio-related sector, focusing on growth in its core markets while managing costs and financial performance in a competitive environment.
Average Trading Volume: 147,145
Technical Sentiment Signal: Buy
Current Market Cap: HK$49.97M
Learn more about 0660 stock on TipRanks’ Stock Analysis page.